MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on tough blood cancers
Disease control OngoingThis early-stage study tests a treatment made from a patient's own immune cells, modified to recognize and attack cancer cells that have returned or not responded to standard therapy. The treatment is given with chemotherapy and an immune-boosting drug. The main goals are to chec…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 26, 2026 11:18 UTC
-
New combo before transplant aims to beat High-Risk leukemia
Disease control TerminatedThis study is for people with high-risk acute leukemia or myelodysplastic syndrome (MDS). It tests a new way to prepare the body for a donor stem cell transplant by combining targeted radiation (TMLI) with two chemotherapy drugs. The goal is to find the safest dose that can kill …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 11:16 UTC
-
Immunotherapy boost may wipe out stubborn leukemia traces
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard targeted therapy (TKIs) can eliminate leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with stable disease but persistent low-level cancer markers will receive t…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 11:16 UTC
-
New drug combo aims to tame stem cell Transplant's worst side effect
Disease control OngoingThis study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers who are…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 11:10 UTC
-
Engineered t cells take aim at Hard-to-Treat leukemias
Disease control OngoingThis early-stage study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatment. The therapy uses a patient's own or donor's immune cells that are genetically modified to recognize and attack cancer cells carry…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 11:09 UTC